the potential of combining pyrimethamine with venetoclax in hma-resistant mds
Published 1 year ago • 187 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:19
the promise of precision medicine in mds
-
1:26
effective immunomodulation with pomalidomide during induction tst for aml and mds
-
1:56
promising approaches and clinical trials in mds
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
4:49
myelofibrosis - causes, symptoms, diagnosis, treatment, pathology
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
7:18
how might luspatercept benefit patients with myelofibrosis?
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
2:16
the potential use of proteomics for predicting relapse in patients with mds undergoing allosct
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
4:48
an insight into the management of cytopenias in mf
-
9:41
the i4mds consortium and immune monitoring in mds
-
3:54
results of medalist: luspatercept reduces transfusion burden in mds
-
3:37
an overview of platelet dysfunction in patients with myeloproliferative neoplasms
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
5:05
higher-risk mds in 2021: pevonedistat, sabatolimab & apr-246
-
12:12
haemostasis made easy!
-
3:07
the impact of blast enumeration & co-occurring myelodysplasia-related mutations in npm1-mutated aml
-
1:49
pid unmet needs: awareness, testing and diagnosis
-
5:34
selecting anticoagulants for acute vte